Humana Reports Third Quarter 2026 Financial Results; Raises Full Year 2026 Adjusted EPS Guidance
Humana reported 3Q26 GAAP EPS of $1.33 and adjusted loss per share of $0.70. YTD GAAP EPS is $16.84. The company raised FY 2026 adjusted EPS guidance to at least $9.50 and GAAP EPS guidance to at least $15.09. Humana also announced strategic expansions and a joint venture with BlackRock. Management will discuss results in a Q&A session today.
How this was made
The 30-second read
Why it matters
The guidance upgrade is the primary market‑moving element, likely prompting short‑term buying interest.
Market read
Guidance raise is a fresh, material development for a large‑cap insurer, offering a clear trading catalyst.
What to watch
Potential headwinds from Star Ratings bonus reductions and Medicaid cost pressures could temper the upside.
Background
Humana's 3Q26 earnings release includes GAAP EPS of $1.33, adjusted loss per share of $0.70, and significant guidance upgrades.
Ticker impact
Humana raised FY 2026 GAAP EPS guidance to at least $15.09 and Adjusted EPS to at least $9.50, up from prior guidance.
upward pressure as investors price in higher earnings expectations
The substantial GAAP EPS lift (more than double) and modest Adjusted EPS raise suggest improved profitability, which typically drives the stock higher.
Market effects
Higher guidance may lift other health‑insurance peers as investors reassess sector earnings outlook.
Positive for U.S. healthcare stocks, modestly supporting broader market indices.
Limited; primarily U.S. market focus.
Counterpoint
If the guidance lift is driven by one‑off items, the stock could be overvalued and vulnerable to a pull‑back.
Key entities
- companyHumana Inc.
U.S. health insurance provider (NYSE:HUM).
